Articles tagged "Recurrence"

2018 American Transplant Congress
Recurrent FSGS Post-Transplantation: Prevalence and Risk Factors
R. Aguiar,¹ A. Gasparini,² P. Chowdhury,¹ D. Game,¹ D. Moutzouris.¹
¹Department of Nephrology and Transplantation, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; ²Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
Introduction: Primary FSGS can recur in the renal allograft and is associated with poor outcomes. The aim of this study was to assess the prevalence…
2018 American Transplant Congress
Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation-
Y. Yamada,¹ K. Hoshino,¹ M. Shinoda,¹ H. Obara,¹ S. Uemoto,³ T. Kaido,³ H. Okajima,³ T. Yagi,⁴ T. Yoshizumi,⁵ Y. Inomata,⁶ T. Hibi,⁶ K. Kubota,⁷ T. Suzuki,⁸ Y. Kitagawa,¹ H. Egawa,² T. Kuroda.¹
¹Surgery, Keio University School of Medicine, Tokyo, Japan; ²Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan; ³Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Kyoto University, Kyoto, Japan; ⁴Hepato-Biliary and Pancreatic Surgery, Okayama University, Okayama, Japan; ⁵Department of Surgery, Kyushu University, Fukuoka, Japan; ⁶Transplantation and Pediatric Surgery, Kumamoto University, Kumamoto, Japan; ⁷Department of Gastroenterological Surgery, Dokkyo Medical University, Tochigi, Japan; ⁸Department of Pediatric Surgery, Fujita Health University School of Medicine, Aichi, Japan.
Background: Multiple studies have failed to reveal an effective method for preventing the recurrence of primary sclerosing cholangitis (PSC) after liver transplantation (LTx). A national…
2018 American Transplant Congress
IgA Recurrence in a Single Center with a Protocol Biopsy Program
M. Merzkani, N. Lepori, M. El Ters, F. Cosio, H. Amer.
Mayo Clinic, Rochester, MN.
The objective of this study was to determine the rate of recurrence of IgA nephropathy in our program aided by protocol biopsies and protocol driven…
2018 American Transplant Congress
Small-for-Size Grafts Increase Recurrence of Hepatocellular Carcinoma in Liver Transplantation beyond Milan Criteria
E. Lee, S. Kim, J. Shim, J. Park, B. Na, S-.J. Park.
Center for Liver Cancer, National Cancer Center, Goyang, Korea.
BACKGROUND: Living donor liver transplantation (LDLT) has been reported to have high rates of hepatocellular carcinoma (HCC) recurrence compared to deceased donor liver transplant (DDLT).…
2018 American Transplant Congress
Treatment Outcomes of Recurrent Primary Focal Segmental Glomerulosclerosis (FSGS) after Kidney Transplantation
R. Aguiar,¹ F. Pereira,² A. Gasparini,³ P. Chowdhury,¹ D. Game,¹ D. Moutzouris.¹
¹Department of Nephrology and Transplantation, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom; ²Department of Renal Medicine, Hospital Dr. Fernando Fonseca, Lisbon, Portugal; ³Department of Health Sciences, University of Leicester, Leicester, United Kingdom.
Introduction: Primary FSGS can recur in the renal allograft and is associated with poor graft outcomes. There is no established therapeutic intervention to prevent or…
2018 American Transplant Congress
Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era
E. Agudelo,^1,2 I. Campos-Varela,³ N. Terrault.^1,2
¹Medicine, University of California San Francisco, San Francisco, CA; ²Surgery, University of California San Francisco, San Francisco, CA; ³Internal Medicine, Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Background: Clearance of HCV under AVT, including DAAs, has been associated with higher risk of rejection, possibly due to the changing immunological environment within the…
2018 American Transplant Congress
Redo Kidney Transplant in FSGS
J. Verbesey, A. Javaid, S. Yi, G. Vranic, A. Gilbert, P. Abrams, S. Ghasemian, J. Moore, B. Thomas, M. Cooper, B. Javaid.
Kidney and Pancreas Transplant Program, MedStar Georgetown Transplant Institute, Washington, DC.
Objective: Analyze risk of graft failure due to recurrent FSGS in patients with prior failed kidney transplants under consideration for a subsequent transplant.Results: We identified…
2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
S. Patel, J. Jin, E. Benedetti, P. West-Thielke.
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…
2017 American Transplant Congress
Multicenter Validation of a Clinicopathologic Risk Score to Predict Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4984 Patients from the US Multicenter HCC Transplant Consortium.
V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.
UCLA, LA
Objective: Recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) negatively impacts survival. Existing risk prediction models either lack external validation or limit their scope…
2017 American Transplant Congress
Significance of Thrombotic Microangiopathy in Renal Allografts.
B. Ozdemir,¹ A. Ok Atilgan,¹ M. Haberal.²
¹Pathology, Baskent University, Ankara, Turkey; ²Transplant Surgery, Baskent University, Ankara, Turkey
Thrombotic microangiopathy (TMA) in the renal allograft is a form of renal capillary injury that may associate with many disorders including calcineurin inhibitor (CI) toxicity,…

« Previous Page
1
…
6
7
8
9
10
…
15
Next Page »